- Home
- IONS vs COOP Comparison
IONS vs COOP Comparison
Compare IONS & COOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- COOP
- Stock Information
- Founded
- IONS 1989
- COOP 2015
- Country
- IONS United States
- COOP United States
- Employees
- IONS N/A
- COOP N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- COOP Finance: Consumer Services
- Sector
- IONS Health Care
- COOP Finance
- Exchange
- IONS Nasdaq
- COOP Nasdaq
- Market Cap
- IONS 6.0B
- COOP 5.3B
- IPO Year
- IONS 1991
- COOP N/A
- Fundamental
- Price
- IONS $37.32
- COOP $98.38
- Analyst Decision
- IONS Buy
- COOP Buy
- Analyst Count
- IONS 18
- COOP 9
- Target Price
- IONS $62.00
- COOP $95.67
- AVG Volume (30 Days)
- IONS 1.5M
- COOP 360.4K
- Earning Date
- IONS 11-06-2024
- COOP 02-07-2025
- Dividend Yield
- IONS N/A
- COOP N/A
- EPS Growth
- IONS N/A
- COOP 18.37
- EPS
- IONS N/A
- COOP 7.72
- Revenue
- IONS $803,067,000.00
- COOP $1,975,000,000.00
- Revenue This Year
- IONS N/A
- COOP $22.91
- Revenue Next Year
- IONS $19.61
- COOP $25.40
- P/E Ratio
- IONS N/A
- COOP $12.72
- Revenue Growth
- IONS 30.57
- COOP 16.66
- 52 Week Low
- IONS $33.33
- COOP $61.38
- 52 Week High
- IONS $54.44
- COOP $103.05
- Technical
- Relative Strength Index (RSI)
- IONS 52.98
- COOP 58.72
- Support Level
- IONS $36.39
- COOP $96.30
- Resistance Level
- IONS $38.90
- COOP $97.84
- Average True Range (ATR)
- IONS 1.33
- COOP 1.76
- MACD
- IONS 0.23
- COOP 0.05
- Stochastic Oscillator
- IONS 51.63
- COOP 89.37
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About COOP Mr. Cooper Group Inc.
Mr. Cooper Group Inc is a home loan servicer. The company focuses on delivering a variety of servicing and lending products. It has operating segments namely Servicing segment which performs operational activities on behalf of investors or owners of the underlying mortgages and mortgage servicing rights, including collecting and disbursing borrower payments, investor reporting, and customer service, The Originations segment originates residential mortgage loans through a direct-to-consumer channel, which provides refinance options for existing customers, and through a correspondent channel, which purchases or originates loans from mortgage bankers and brokers, and the Corporate segment. The Servicing segment of the company generates maximum revenue.